Last reviewed · How we verify
Combivent
At a glance
| Generic name | Combivent |
|---|---|
| Also known as | Bronchodilator, Ipratropium - Salbutamol |
| Sponsor | Dr. Denis O'Donnell |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ventilator Adapters for Combivent Respimat (PHASE4)
- Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (PHASE4)
- Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients. (PHASE4)
- Effectiveness of the Aeroneb in Acute Severe Asthma (NA)
- Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- Breath-Actuated Nebulizer Versus Conventional Continuous-Output Nebulizer in Pediatric Asthma Patients (NA)
- Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children (NA)
- A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combivent CI brief — competitive landscape report
- Combivent updates RSS · CI watch RSS
- Dr. Denis O'Donnell portfolio CI